• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy.

作者信息

Tursi Antonio, Brandimarte Giovanni, Torello Monica

机构信息

Digestive Endoscopy Unit, L. Bonomo Hospital, Andria, Bari, Italy.

出版信息

J Clin Gastroenterol. 2004 Apr;38(4):360-3. doi: 10.1097/00004836-200404000-00011.

DOI:10.1097/00004836-200404000-00011
PMID:15087696
Abstract

OBJECTIVE

Mucosa-associated lymphoid tissue, which has a follicular structure closely resembling Peyer patches, is absent in the normal gastric mucosa, but it can develop in several chronic conditions. Since we recently detected hepatitis C virus-RNA in gastric mucosa-associated lymphoid tissue of patients with chronic hepatitis C, we tried to treat hepatitis C virus infection to evaluate the effect of antiviral therapy on gastric mucosa-associated lymphoid tissue.

METHODS

Eighteen patients (12 men and 6 women; mean age: 52 years, range: 33-71 years) affected by chronic hepatitis C virus and with gastric mucosa-associated lymphoid tissue were enrolled. We enrolled only patients hepatitis C virus-positive, mucosa-associated lymphoid tissue-positive, and Helicobacter pylori-negative (8 patients) or hepatitis C virus-positive patients in whom anti-H. pylori therapy did not obtain disappearance of gastric mucosa-associated lymphoid tissue (10 patients). Hepatitis C virus was evaluated by hepatic biopsy with histologic evaluation and serologic examination; Gastric mucosa-associated lymphoid tissue was scored using Wotherspoon score. All patients were treated with recombinant leukocyte interferon-alpha-2b plus oral ribavirin for 6 months. The hepatitis C virus RNA was assayed at entry and at 3 months after stopping treatment. Virologic response was defined as undetectable levels of serum hepatitis C virus RNA 3 months after stopping treatment; esophagogastroduodenoscopy was repeated at this time to evaluate the effect of anti-hepatitis C virus therapy on acquired gastric mucosa-associated lymphoid tissue.

RESULTS

Two (11.11%) patients were withdrawn from the study. Hepatitis C virus cure was obtained in 11/16 patients (68.75%), and in all of them we obtained disappearance of gastric mucosa-associated lymphoid tissue (P < 0.01). Hepatitis C virus infection persisted, but with very lower levels, in 5 of 16 patients (31.25%): in 3 patients gastric mucosa-associated lymphoid tissue persisted (but in 2 it decreased from grade 3 to grade 2), while in 2 it disappeared.

CONCLUSIONS

We showed clearly that there is a strict correlation between hepatitis C virus infection and acquired MALT, obtaining the disappearance of this acquired immunologic acquired gastric tissue curing hepatitis C virus infection. However, further studies are needed to clarify there is the same correlation between hepatitis C virus infection and gastric mucosa-associated lymphoid tissue lymphomas in hepatitis C virus-positive patients.

摘要

相似文献

1
Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy.
J Clin Gastroenterol. 2004 Apr;38(4):360-3. doi: 10.1097/00004836-200404000-00011.
2
Detection of HCV RNA in gastric mucosa-associated lymphoid tissue by in situ hybridization: evidence of a new extrahepatic localization of HCV with increased risk of gastric malt lymphoma.通过原位杂交检测胃黏膜相关淋巴组织中的丙型肝炎病毒RNA:丙型肝炎病毒新的肝外定位证据及胃黏膜相关淋巴组织淋巴瘤风险增加
Am J Gastroenterol. 2002 Jul;97(7):1802-6. doi: 10.1111/j.1572-0241.2002.05848.x.
3
Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.隐匿性乙肝病毒感染与慢性丙型肝炎联合治疗早期丙型肝炎病毒复制的抑制
J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):172-5.
4
Effect of anti-viral therapy for occult hepatitis C virus infection.抗病毒治疗对隐匿性丙型肝炎病毒感染的疗效
Aliment Pharmacol Ther. 2006 Apr 15;23(8):1153-9. doi: 10.1111/j.1365-2036.2006.02886.x.
5
Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.丙型肝炎病毒阳性混合型冷球蛋白血症的干扰素治疗:影响治疗效果的病毒和宿主因素
Ital J Gastroenterol Hepatol. 1997 Aug;29(4):343-50.
6
Long-term follow-up of disappearance of gastric mucosa-associated lymphoid tissue after anti-Helicobacter pylori therapy.抗幽门螺杆菌治疗后胃黏膜相关淋巴组织消失的长期随访
Am J Gastroenterol. 1997 Oct;92(10):1849-52.
7
New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin.肝移植后使用利巴韦林治疗丙型肝炎病毒感染的新方法。
J Hepatol. 1995;23 Suppl 2:22-5.
8
Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin.聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎患者的早期丙型肝炎病毒变化及持续应答
Liver Int. 2005 Feb;25(1):91-5. doi: 10.1111/j.1478-3231.2005.1040.x.
9
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.慢性丙型肝炎患者经α干扰素治疗获得持续应答后,长期的组织学改善及肝内可检测到的丙型肝炎病毒RNA消失。
Ann Intern Med. 1997 Nov 15;127(10):875-81. doi: 10.7326/0003-4819-127-10-199711150-00003.
10
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.单用干扰素α-2b或联合利巴韦林治疗慢性丙型肝炎复发。国际肝炎介入治疗组
N Engl J Med. 1998 Nov 19;339(21):1493-9. doi: 10.1056/NEJM199811193392102.

引用本文的文献

1
Hepatitis C virus and non-Hodgkin's lymphomas: A minireview.丙型肝炎病毒与非霍奇金淋巴瘤:一篇综述
J Adv Res. 2017 Mar;8(2):131-137. doi: 10.1016/j.jare.2016.11.005. Epub 2016 Dec 12.
2
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.丙型肝炎抗病毒治疗作为惰性B细胞淋巴瘤的治愈性疗法。
World J Gastroenterol. 2016 Oct 14;22(38):8447-8458. doi: 10.3748/wjg.v22.i38.8447.
3
Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options.丙型肝炎病毒与非霍奇金淋巴瘤:流行病学数据及治疗方案的荟萃分析
World J Hepatol. 2016 Jan 18;8(2):107-16. doi: 10.4254/wjh.v8.i2.107.
4
Hepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral Therapy.丙型肝炎相关 B 细胞非霍奇金淋巴瘤:临床特征及抗病毒治疗的作用。
J Clin Transl Hepatol. 2015 Jun 28;3(2):134-9. doi: 10.14218/JCTH.2015.00011. Epub 2015 Jun 15.
5
Primary hepatic mucosa-associated lymphoid tissue (MALT) lymphoma.原发性肝黏膜相关淋巴组织(MALT)淋巴瘤。
Clin J Gastroenterol. 2013 Apr;6(2):150-5. doi: 10.1007/s12328-013-0362-5. Epub 2013 Feb 7.
6
The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas.感染因子、抗生素及抗病毒治疗在结外边缘区淋巴瘤和其他低级别淋巴瘤治疗中的作用。
Curr Treat Options Oncol. 2015 Jun;16(6):28. doi: 10.1007/s11864-015-0344-6.
7
Non-Hodgkin lymphoma and hepatitis C: where we are and what next?非霍奇金淋巴瘤与丙型肝炎:现状与未来走向?
Pathol Oncol Res. 2015 Jan;21(1):1-7. doi: 10.1007/s12253-014-9845-z. Epub 2014 Oct 2.
8
Cumulative Epigenetic Abnormalities in Host Genes with Viral and Microbial Infection during Initiation and Progression of Malignant Lymphoma/Leukemia.病毒和微生物感染宿主基因在恶性淋巴瘤/白血病起始和进展中的累积表观遗传学异常。
Cancers (Basel). 2011 Feb 4;3(1):568-81. doi: 10.3390/cancers3010568.
9
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.与丙型肝炎病毒感染相关的惰性B细胞淋巴瘤:临床和病毒学特征以及抗病毒治疗的作用
Clin Dev Immunol. 2012;2012:638185. doi: 10.1155/2012/638185. Epub 2012 Aug 26.
10
Some patients with NHL possessed immunoreactivity to gliadin and to cow's milk proteins.一些非霍奇金淋巴瘤患者对麦醇溶蛋白和牛奶蛋白具有免疫反应性。
Int J Hematol. 2009 Sep;90(2):212-216. doi: 10.1007/s12185-009-0383-5. Epub 2009 Jul 17.